SAB Biotherapeutics SABS
NASDAQ SABS
$2.81 -0.08 (-2.60%)
As of: Oct 21, 2026 · 3:56 PM EDT

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

Updated

SAB Biotherapeutics' Convertible Debt was $541,644 in Q2 2023, unchanged from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,135.76 Bn 1,104.34 Bn 19.71 Bn
2 Johnson & Johnson 619.07 Bn 537.60 Bn 17.26 Bn
3 AbbVie 503.11 Bn 476.22 Bn 12.70 Bn
4 Merck 370.23 Bn 324.61 Bn 12.21 Bn
5 Novartis Ag 298.76 Bn 262.75 Bn 11.24 Bn
6 Astrazeneca 261.14 Bn 234.83 Bn 12.86 Bn
7 Amgen 237.54 Bn 192.94 Bn 7.24 Bn
8 Gilead Sciences 191.65 Bn 165.84 Bn 6.22 Bn
9 Pfizer 170.26 Bn 116.90 Bn 10.94 Bn
10 SAB Biotherapeutics 224.90 Mn -192.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 541,644.00
Mar 31, 2023 541,644.00
Dec 31, 2022 541,644.00
API Access

SAB Biotherapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=SABS&period=max&api_key=YOUR_API_KEY